Baran, ÇağdaşDurdu, SerkanDalva, KlaraZaim, ÇağınDoğan, ArinGürman, GünhanArslan, ÖnderAkar, Ahmet Ruchan2021-11-262021-11-262012-09Baran, Ç. vd. (2012). "Effects of preoperative short term use of atorvastatin on endothelial progenitor cells after coronary surgery: A randomized, controlled trial". Stem Cell Reviews and Reports, 8(3), 963-971.1550-8943https://doi.org/10.1007/s12015-011-9321-zhttps://link.springer.com/article/10.1007%2Fs12015-011-9321-zhttps://pubmed.ncbi.nlm.nih.gov/22076751/http://hdl.handle.net/11452/22809We investigated the effects of short-term use of atorvastatin on CD34+/VEGF-R2+/CD133+/CD45- endothelial progenitor cell (EPC) count after on-pump coronary artery bypass surgery (CABG). Between Feb-2010 and May-2010, we randomly assigned, in a placebo-controlled, double-blind study, 60 consecutive patients who underwent isolated, first-time CABG to receive either 14-day atorvastatin (40 mg/day) or placebo preoperatively. Urgent CABG and recent myocardial infarction were excluded. EPCs were quantified (cells/mu l) by flow cytometric phenotyping obtained from venous blood samples collected preoperatively (T-1), 6-hours (T-2), and on the 5th day postoperatively (T-3). Levels of markers of inflammation and serum cardiac troponin I were also measured preoperatively and daily until day-5 after surgery. There were no differences in baseline risk factors including cholesterol profiles, and EuroSCORES between the groups. The composite primary end-point, favored statin group with higher amount of circulating, early EPC count (cells/mu l) at all time points compared with placebo (T-1, 2.30 +/- 0.02 versus 1.58 +/- 0.03, p < 0.001; T-2, 5.00 +/- 0.06 versus 2.19 +/- 0.06, p < 0.001; T-3, 3.03 +/- 0.08 versus 1.78 +/- 0.02, p < 0.001). Postoperative hsCRP rise were inversely correlated with EPC count, and were significantly lower in the statin group (T-1, 0.8 +/- 0.1 versus 2.2 +/- 1.5, p < 0.001; T-2, 72.9 +/- 3.2 versus 96.0 +/- 3.6, p < 0.001; T-3, 4.3 +/- 1.2 versus 11.4 +/- 4.1, p < 0.001). Furthermore, the incidence of postoperative atrial fibrillation was significantly lower in the statin group compared to placebo (3.3% versus 23%, p = 0.02). Short-term atorvastatin use increases circulating early EPCs both pre- and post-operatively and is associated with better preservation of sinus rhythm and reduced hsCRP levels.eninfo:eu-repo/semantics/closedAccessCell biologyResearch & experimental medicineEndothelial progenitor cellsStatinsCABGC-reactive proteinCardiopulmonary bypassMyocardial damagePeripheral-bloodCardiac-surgeryArtery-diseaseStatin therapyBone-marrowAngiogenesisRegenerationIncreaseAgedAnti-inflammatory agentsC-reactive proteinCoronary artery bypassCoronary artery diseaseEndotheliumFemaleHeptanoic acidsHumansLipidsMaleMiddle agedPreoperative periodPyrrolesStem cell transplantationTreatment outcomeTroponin IArticle0003073331000302-s2.0-848655341639639718322076751Cell & tissue engineeringCell biologyMedicine, research & experimentalEndothelial Progenitor Cells; Acetyl Low Density Lipoprotein; Chemokine CXCL12Antiinflammatory agentAtorvastatinC reactive proteinHeptanoic acid derivativeLipidPyrrole derivativeTroponin IAgedPathologyArticleBloodClinical trialControlled clinical trialControlled studyCoronary artery bypass graftCoronary artery diseaseEndotheliumFemaleHumanMaleMetabolismMiddle agedPreoperative periodRandomized controlled trialStem cell transplantationTreatment outcome